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Abstract
Heart failure (HF) is a major public health problem because it is one of the most common 
causes of morbidity and mortality in Western countries, with a prevalence of 1–2% in 
the adult population, rising to ≥10% in those age >70 years. In addition to the “classic” 
co-morbidities, such as COPD, arterial hypertension, diabetes, renal failure, etc., there 
are other conditions frequently found in patients with heart failure that many times are 
underestimated. One example are anemia and iron deficiency (ID). ID, regardless of 
anemia impair exercise tolerance, symptoms and quality of life, with a strong negative 
prognostic impact on hospitalization and mortality rate. Despite strong evidence of high 
prevalence of ID in these patients and current guidelines recommendations, the diag-
nosis of ID and its monitoring over time still have low priority for physicians in clinical 
practice. Consequently ID is under-treated; furthermore current therapies, in particular 
i.v. iron as ferric carboxymaltose, though effective, turn out to be poorly managed by 
clinicians. ID should be considered more in real world HF healthcare settings to improve 
patients’ quality of life and outcome.
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1. Heart failure and comorbidity
Heart failure (HF) is a major public health problem because it is one of the most common 
causes of morbidity and mortality in Western countries, with a prevalence of 1–2% in the 
adult population, rising to ≥10% in those age >70 years [1]. Regardless of the cause, HF is 
a life threatening syndrome and therefore requires specific treatments aimed at reducing 
symptoms and improving quality and/or quantity of life. The overall aging of the population, 
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that has been recorded over the last few decades, has led to an increase in the prevalence of 
chronic pathologies, from which derives an increase in the number of elderly people that have 
more than one disease at the same time. Patients with HF have multiple co-morbid conditions 
and 60% of them have five or more [2, 3]. In addition to the “classic” co-morbidities, such as 
COPD, arterial hypertension, diabetes, renal failure, etc., there are other conditions frequently 
found in patients with heart failure that many times are underestimated. One example are 
anemia and iron deficiency (ID): the presence of ID, regardless of concomitant anemia, has 
been shown to worsen symptoms and patient prognosis.
Management of co-morbidities is a key point of HF patients care, to cut down this chronic 
epidemic disabling syndrome.
2. Iron deficiency in heart failure
2.1. Epidemiology
Iron deficiency (ID) is a frequent co-morbidity found in 35–50% of patients with HF; it is the 
most common cause of anemia in patients with HF but, most importantly, ID occurs in 46% of 
non-anemic patients with stable systolic HF [4, 5].
Despite its high prevalence, this co-morbidity was underdiagnosed for several years. ID can 
be present in patients with HF regardless of the presence of anemia and can be classified 
in absolute or functional ID, by determining ferritin levels: ferritin <100 μg/l if absolute ID, 
reflecting depleted iron stores due to low dietary intake, blood loss, etc., or ferritin between 
100 and 300 μg/l and the transferrin saturation (<20%) if functional ID, when iron delivery to 
target cells is impaired despite normal or overly abundant iron stores, due to chronic inflam-
mation, etc. [6, 7].
ID in chronic HF is more frequent in women and in patients with advanced HF, as shown 
by Klip data [4]: in an international cohort of 1506 patients with chronic HF, ID was closely 
related to disease severity, assessed using NYHA functional class (Figure 1) and NT-proBNP 
levels.
ID frequently overlaps with anemia and chronic kidney disease; in this study only the 7% of 
patients had anemia without ID (related to renal dysfunction, hemodilution, vitamins or folic 
deficiency, hematologic cause) [8–10].
As reported in a study of Ponikowski, ID prevalence was of 37% in a cohort of 546 CHF 
patients (32 ± 4 vs. 57 ± 10% in subjects without vs. with anemia) [11]. This study also showed 
that ID, but not anemia, was related to an increased risk of mortality after 3 years follow-up 
(Figure 2).
In the setting of acute heart failure patients, ID prevalence is even higher (50–80%) [12, 13].
In preserved ejection fraction HF it is also high, as showed in subgroups analysis.
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Figure 1. ID and anemia stratified by NYHA functional class. Modify by Iron deficiency in chronic heart failure: an 
international pooled analysis.
Figure 2. ID was related to an increased risk of mortality after 3 years follow-up. Modify by Iron deficiency: an ominous 
sign in patients with systolic chronic heart failure.
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2.2. Clinical and prognostic impact
In patients with chronic HF, ID, regardless of the presence of anemia, is a strong and indepen-
dent predictor of outcome, in fact it is associated with higher mortality and hospitalization 
rates [13, 14]. Moreover, ID has been shown to worsen HF symptoms and to impair exercise 
tolerance, with poor quality of life [11]. The explanation is simple and is related to the key role 
of iron in human homeostasis. Iron, as is well known, is essential for erythropoiesis, as part of 
the hemoglobin, ad so for oxygen transport. Moreover, as is perhaps less well known [15], iron 
is a fundamental co-factor for other several processes, such as normal activity of key enzymes 
of the citric acid cycle and ROS scavenging enzymes. It plays an important role in generation 
of ATP, necessary for all cellular process and for muscles contractility. Recent in vitro evi-
dence show that ID directly affects human cardiomyocytes function, impairing mitochondrial 
respiration, and reducing contractility and relaxation. In this regard, a special characteristic 
of physical stress in heart failure is the early shift from aerobic to anaerobic metabolism due 
to the compromission of oxidative capacity [16]. It is therefore clear that ID can only worse 
exercise intolerance and sub-maximal exercise resistance, heavily compromising quality of 
life. Restoration of intracellular iron levels can reverse these effects [17]. Exercise tolerance 
was analyzed in 443 patients with systolic chronic heart failure: only ID (and not anemia) was 
significantly associated with reduced peak oxygen consumption (VO
2
) (Figure 3) [18].
Another study from Okonko confirm these data on 157 chronic HF patients: ID was related 
to impaired exercise capacity and survival and appeared prognostically more ominous than 
anemia [19]. In the same way, it is known that ID therefore has a negative impact on Quality 
Figure 3. ID is significantly associated with reduced peak VO
2
. Modify by Iron deficiency predicts impaired exercise 
capacity in patients with systolic chronic heart failure.
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of Life, measured by Minnesota Living with Heart Failure questionnaire, and this is indepen-
dent of the presence of anemia. Lower TSAT is related to lower QoL; the correlation is not 
so clear for hemoglobin level [20]. Furthermore, ID is a strong and independent predictor of 
outcome in HF patients, as shown in several studies. In the large international pooled cohort 
of 1506 chronic HF patients by Klip, ID identifies those with an enhanced risk for death, 
independently of other well-established predictors of outcome, and appears to have greater 
predictive power than anemia (Figures 4 and 5) [4].
For several years, we consider only anemia as negative prognostic factor, but definitely, the 
negative effect of iron deficiency seems to be stronger.
2.3. Treatments
Given the clinical importance of ID in HF patients, restoration of iron stores to normal lev-
els should be a therapeutic goal in clinical practice [21], as well as addressing its underlying 
causes.
Regardless the known poor efficacy, oral iron supplementation is almost always the first line 
therapy for ID, due to their low cost and ease of administration. Ferrous sulfate is the most 
commonly used. However, gastrointestinal side effects are common and can often compro-
mise the therapy compliance. Moreover, the enteric absorption may be reduced by quite a lot 
of factors: interaction with other drugs or food, edema and congestion of the gastrointestinal 
mucosa, high hepcidin level in HF [22].
Figure 4. ID is a strong and independent predictor of outcome in HF patients. Modify by Iron deficiency in chronic heart 
failure: an international pooled analysis.
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In addition, iron deficiency in HF patients is severe in the most of the case (on average 1.5–2 g 
of iron); considering that a tablet has 80 mg of iron (with a bioavailability of 10%), the supple-
ment must be prolonged for months to be effective. As we will see later, the use of iron salt is 
not supported by clinical trials data.
Intravenous iron may solve these problems and may be more suitable both for physicians and 
patients [23, 24]. Intravenous iron complex used for ID are ferric gluconate, ferric carboxy-
maltose, ferric hydroxide sucrose, and ferric hydroxide dextran. A big advantage of intrave-
nous iron is the rapid improvement in iron parameters [25]: it is not influenced by hepcidin 
absorption blocking mechanisms. Probably it is also cost-effectiveness, because reduce hospi-
talization and improved quality of life [26].
Comparative data from the different complex are not available. However, ferric carboxymalt-
ose has the advantage of high dose (500 mg) formulation [27]: it seems to be particularly 
effective in severe ID, that is frequently diagnosed in HF patients, and well tolerated. One or 
two injections are usually adequate to reach the therapeutic target.
The most of clinical trials on ID correction in HF evaluated the use of ferric carboxymaltose.
2.4. From clinical trials to guidelines
The FAIR-HF study was the first big multicentric, prospective, double-blind, randomized trial 
[28] published in the contest of iron supplementation in HF, almost 10 years ago. Patients 
were randomized to receive intravenous ferric carboxymaltose or placebo. Quality of life, 
symptoms, distance during 6-minute walking test were significantly improved after treatment 
Figure 5. Mortality among groups of ID and/or anemia (* p<0.01; † p<0.001). Modify by Iron deficiency in chronic heart 
failure: an international pooled analysis.
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with ferric carboxymaltose in patients with chronic HF and ID, with or without anemia. A 
such strong result was really not expected. The clinical improvement was confirmed in sev-
eral patient’s subgroups, based on hemoglobin level, renal function, gender, ejection fraction. 
Moreover, intravenous iron improved patient’s global assessment and NYHA class in both 
anemic and non-anemic patients with HF.
Another trial, CONFIRM-HF [11], was performed in heart failure patients with iron defi-
ciency. It was a multicentre, double-blind, placebo-controlled trial that enrolled 304 ambula-
tory symptomatic HF patients with left ventricular ejection fraction ≤45%, elevated natriuretic 
peptides, and iron deficiency. The primary endpoint was the exercise capacity. Ferric car-
boxymaltose significantly improved 6 minutes walking test distance from baseline to week 24. 
Moreover the treatment may be associated with risk reduction of hospitalization for worsen-
ing HF at week 52; although it was a secondary endpoint, it had an amazing relevance.
The EFFECT-HF trial was a multicenter, randomized 1:1, open label, standard of care con-
trolled trial [29]; the primary endpoint was change in peak VO
2
 from baseline to week 24. 
Again, intravenous ferric carboxymaltose significantly improve exercise capacity in heart 
failure patients. The main limit of this trial was that standard of care not include intravenous 
iron, but just oral formulation.
So, treatment with intravenous ferric carboxymaltose in patients with HF and iron deficiency 
improves iron stores.
Whether ferric carboxymaltose seems to be associated with an improved clinical condition 
and outcome in these high-risk patients, further study are necessary.
In the last few months was performed an individual patient meta-analysis on the topic [30]. 
Individual patient data were extracted from randomized clinical trials comparing ferric car-
boxymaltose with placebo in patients with systolic HF and ID. The endpoints were recurrent 
cardiovascular hospitalizations and cardiovascular mortality. About 839 patients, of whom 
504 were randomized to FCM, were included. Ferric carboxymaltose was associated with a 
reduction in cardiovascular hospitalizations.
The results of this analysis show that treatment of ID with e.v. ferric carboxymaltose in ambu-
latory systolic HF patients with ID may decrease recurrent cardiovascular hospitalizations.
These findings suggest that intravenous iron therapy may potentially represent a beneficial 
addition to the standard medical management of HF (Table 1).
Although the individual patient meta-analysis is the best type of statistical analysis, a specific 
randomized clinical trial is needed.
About oral iron therapy, the most relevant trial published is the IRONOUT trial [31]. It was 
a double-blind, placebo-controlled randomized clinical trial of patients with reduced ejec-
tion fraction (<40%). Oral iron polysaccharide (150 mg twice daily) was compared to placebo. 
Among patients with HF with iron deficiency, high-dose oral iron did not improve exercise 
capacity over 16 weeks and did not change iron biomarkers. Probably the absorption from 
Heart Failure and Iron Deficiency
http://dx.doi.org/10.5772/intechopen.79358
73
the gastrointestinal tract is limited by foods, medications, edema of the intestinal mucosa due 
to venous congestion [32], upregulation of hepcidin [33]. Moreover, each tablet has a dose 
of iron that is very low (compared with the massive iron deficiency that affects heart failure 
patients), so the treatment should be prolonged for several months. These results do not sup-
port use of oral iron supplementation in patients with HfrEF.
Based on the actual evidence, the current ESC guidelines on diagnosis and treatment of HF [1] 
recommend very clearly that all patients with HF have to be screened for ID based on serum fer-
ritin and TSAT (Class I, Level C) (Figure 6). The dosage of ferritin and TSAT has the same strong 
of recommendation of the evaluation of hemoglobin and white cells, sodium, potassium, urea, 
creatinine, glucose, liver function test and other routine analysis. We also have the specific rec-
ommendation regarding the treatment: intravenous ferric carboxymaltose should be considered 
in symptomatic patients with HFrEF and iron deficiency in order to alleviate HF symptoms, 
and improve exercise capacity and quality of life (Figure 7). It is important to note that when the 
guidelines were published there was not available the results of meta-analysis from Anker that 
showed the benefits in terms of heart failure hospitalization and cardiovascular death.
Based on the results of FAIR-HF and CONFIRM-HF trials, the 2017 ACC/AHA/HAS guide-
lines for management of HF [34, 35] also state that IV iron might be reasonable in NYHA Class 
II to III patients with ID (Class II, Level B) to improve QoL and functional status.
2.5. Real world data
In addition to clinical trials and guidelines, real world data confirm not only the high preva-
lence and the negative prognostic impact of ID in HF patients, but also the efficacy of i.v. iron, 
in particular of FCM, to treat this important comorbidity. But, despite this background, real 
world data show also what is still happening today in clinical practice, that is the poor atten-
tion paid to the diagnosis and treatment of ID in HF patients.
Recurrent event outcomes FCM (N = 504) Placebo (N = 335) p
NB. Total events (incidence per 100 patient-years 
of follow-up)
CV hospitalization and CV death 69 (23.0) 92 (40.9) 0.009
HF hospitalization and CV death 39 (13.0) 60 (26.7) 0.011
CV hospitalization and all-cause death 71 (23.7) 94 (41.8) 0.009
HF hospitalization and all-cause death 41 (13.7) 62 (27.6) 0.011
All-cause hospitalization and all-cause death 108 (36.1) 118 (52.5) 0.060
HF hospitalization 22 (7.3) 43 (19.1) 0.003
CV hospitalization 52 (17.4) 75 (33.3) 0.004
All-cause hospitalization 89 (29.7) 99 (44.0) 0.056
Modify by Effects of ferric carboxymaltose on hospitalizations and mortality rates in iron-deficient heart failure patients: 
an individual patient data meta-analysis.
Table 1. Results from individual patient meta-analysis by Anker et al.
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The PReP prospective Registry [36] show that in a real world setting of 1198 ambulatory patient 
with HF, ID was present in 42.5% of the study participants, and not previously known in any 
of them. The prevalence of anemia was 18.9%, and it was known prior to enrolment only in 
4.8% of participants. ID, more common in anemic patients, was an independent predictor of 
reduced exercise tolerance. The authors conclude that despite high prevalence and clinical 
relevance, ID and anemia are often unappreciated in real world ambulatory HF patients.
Regarding treatment, although several Clinical trials studied FCM use and efficacy, real world 
evidence is limited. Nunes data [37] show that in 459 HF outpatient with ID treated with FCM 
therapy, Hb and TSAT increased and FCM was well tolerated; moreover higher doses of FCM 
(500 mg−1000 mg and 100-3000 mg) showed a significant higher efficacy compared with lower 
dose (500 mg).
Figure 6. Recommendations for diagnostics tests in patients with heart failure. Modify by ESC HF guidelines.
Figure 7. Recommendations for the treatment of other comorbidities in patients with heart failure. Modify by ESC HF 
guidelines.
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Figure 9. Type of iron therapy at discharge. Modify by Carmes-1 study.
But, despite these data, current guidelines and the results of IRONOUT trial, in real world 
oral iron is often the first line therapy for ID in HF, that remain an underdiagnosed comor-
bidity as showed by Wienbergen in the sub-study of the RAID-HF registry [38], aimed to 
obtain information on ID management in a large real world cohort of HF patients. The results 
showed that among 1484 participants, iron status was determined only in 62% of them (and 
55% had ID), despite it was a registry focusing on ID in HF! Furthermore only 8.5% of ID 
patients received iron therapy, most of them orally and just 11 of the 13 patients treated with 
i.v. iron received FCM. Patients on iron therapy had higher NYHA class and were predomi-
nantly anemic; physicians analyzed and treated ID only in severe HF or in presence of anemia 
(Figure 8); and it is not evidence based because the efficacy of iron therapy is demonstrated 
independently of anemia.
Figure 8. ID is under-treated, especially in non-anemic patients. Modify by RAID-HF registry.
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These real word data, that confirm the results of our CARMES 1 study in a cohort of 418 
hospitalized HF patients in Italy in which ID was underdiagnosed and undertreated [39] 
(Figure 9), underline that diagnostic and therapeutic efforts on ID management in HF are still 
low in clinical practice.
3. Conclusion
Iron deficiency, regardless of anemia, is a frequent co-morbidity in HF patients, which impair 
exercise tolerance, symptoms and quality of life, with a strong negative prognostic impact on 
hospitalization and mortality rate.
Despite strong evidence of high prevalence of ID in these patients and current guidelines 
recommendations, the diagnosis of ID and its monitoring over time still have low priority 
for physicians in clinical practice. Consequently ID is under-treated; furthermore current 
therapies, in particular i.v. iron as FCM, though effective, turn out to be poorly managed by 
clinicians.
Therefore ID should be considered more in real world HF healthcare settings to improve 
patients’ quality of life and outcome.
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